Colgate-Palmolive (NYSE: CL) stock price gained 32% from $60 at 2018 end to around $78 currently, primarily due to favorable changes in its revenues. During this period, the company witnessed a 14% increase in revenues, and a 3.3% drop in the outstanding share count further helped support revenue per share. Additionally, helped by a rise in the P/S multiple, the company’s stock price has risen 32%, but still underperformed the S&P 500, which returned a little over 50% over the same period.
In our interactive dashboard, Why Colgate-Palmolive Stock Moved: CL Stock Has Gained 32% Since 2018, we break down the factors behind this move.
(A) CL’s Total Revenue has grown 14% from $15.5 billion in FY 2018 to $17.7 billion on an LTM basis
- CL’s total revenue rose steadily from $15.5 billion in FY ’18 to $17.4 billion in FY ’21, and as demand has remained strong since the pandemic, with sales rising to $17.7 billion currently.
- Colgate-Palmolive is a leading manufacturer and distributor of household, health care, personal care, and veterinary products, operating in markets across the world.
- As of FY ’21, Oral, Personal and Home Care sales make up the majority of CL’s total revenue, bringing in 81% of the company’s sales, with Pet Nutrition making up the remaining 19%.
- For additional details about CL’s revenues and comparison to peers, see Colgate-Palmolive (CL) Revenue Comparison
- Despite Steady Gains Since 2018, Colgate-Palmolive Stock Has Underperformed The S&P
- Colgate-Palmolive Stock Has Returned Just 6% Since Late 2017- Here’s Why
- Colgate-Palmolive Stock Has Underperformed The S&P Since 2018- Here’s Why
- Up 8% Last Month, Colgate-Palmolive Stock Looks Unlikely To Continue Its Rally
- Can Colgate-Palmolive Stock Sustain Its Outperformance?
- Colgate-Palmolive Stock Looks Unlikely To Continue Its Rally Next Month
(B) Revenue per share (RPS) increased 18% from $18.00 in FY 2018 to $21.24 currently
- Colgate-Palmolive revenue rose from $15.5 billion in FY ’18 to $17.7 billion currently, while the outstanding share count decreased from around 863.6 million in FY 2018 to 835.1 million currently.
- Due to this, RPS has jumped from $18.00 in FY ’18 to $21.24 currently.
(C) Price-To-Sales (P/S) multiple for Colgate-Palmolive rose steadily from 3.3x in 2018 end to 4.4x by 2020 end but has since pulled back to 3.7x currently, still around 10% higher than what it was in late 2018
- Colgate-Palmolive’s performance since 2018-end saw its P/S multiple rise from 3.3x in 2018 to 4.4x in 2020.
- Despite CL’s consistent sales performance over the years, the P/S multiple has dropped to 3.7x currently due to increased uncertainty surrounding global economic conditions.
- For additional details about the company’s historical returns and comparison to peers, see Colgate-Palmolive (CL) Stock Return.
|S&P 500 Return||-7%||-20%||70%|
|Trefis Multi-Strategy Portfolio||-6%||-22%||213%|
 Month-to-date and year-to-date as of 12/30/2022
 Cumulative total returns since the end of 2016